| Name | Recombinant Human CD39L1 (C-6His) |
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Ecto-Nucleoside Triphosphate Diphosphohydrolase 2 is produced by our Mammalian expression system and the target gene encoding Thr29-Asp460 is expressedwith a 6His tag at the C-terminus. |
| Accession # | Q9Y5L3 |
| Host | Human Cells |
| Species | Human |
| Predicted Molecular Mass | 48 KDa |
| Buffer | Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 5mM CaCl2, 10% Glycerol, pH 7.4. |
| Form | Liquid |
| Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2
Background
CD39L1 protein (ENTPD2 or NTPDase2) is a member of the ecto-nucleoside triphosphate diphosphohydrolase family which the main role is termination of purinergic signaling. CD39L1 gene encodes a precursor protein with 495 amino acid residues which generates a 437 amino acid residues mature protein after processing. It is an ecto-nucleotidase that found on the surface of vascular adventitial cells and accessory vascular cells. CD39L1 is a Ca2+- and Mg2+-dependent enzyme that activates platelets by preferentially converting ATP to ADP. CD39L1 plays a role in regulating thrombosis and inflammation which is considered to be a therapeutic target for thromboregulation and the treatment of vascular inflammation. Alternative splicing of CD39L1 gene results in multiple transcript variants.
Note
For Research Use Only , Not for Diagnostic Use.